FDA Urges Centralized Clinical Trial Monitoring Over Frequent On-Site Visits – Guidance
This article was originally published in The Gray Sheet
Executive SummaryClinical trial sponsors should make greater use of off-site centralized monitoring, in place of frequent on-site visits, to ensure the quality of their trials, FDA emphasizes in new draft guidance.
You may also be interested in...
News from FDA this week includes a finalized guidance to clinical trial sponsors on study monitoring, interest in an electronic portal to facilitate the launch of an international single-audit program and a planned meeting to discuss ethical issues for pediatric product development.
News on a Synthes sentencing, Riata recall and other regulatory developments.